Shelby Reed, Assistant Professor

Please note: Shelby has left the "Economics" group at Duke University; some info here might not be up to date.

Office Location:  North Pavillion
Email Address: send me a message

Education:

Ph.D.University of Maryland, College Park1998
Representative Publications

  1. SD Reed, Y Li, S Kamble, D Polsky, FL Graham, MT Bowers, GP Samsa, S Paul, KA Schulman, DJ Whellan, BJ Riegel, Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions., Circulation. Cardiovascular quality and outcomes, vol. 5 no. 1 (January, 2012), pp. 113-9, ISSN 1941-7705 [doi]  [abs]
  2. EM Dewitt, CA Grussemeyer, JY Friedman, MA Dinan, L Lin, KA Schulman, SD Reed, Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 15 no. 2 (January, 2012), pp. 277-83, ISSN 1524-4733 [doi]  [abs]
  3. SD Reed, When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 14 no. 8 (December, 2011), pp. 1055-6, ISSN 1524-4733 [doi]
  4. SD Reed, ZJ Eapen, KA Schulman, End point selection in acute decompensated heart failure clinical trials: economic end points., Heart failure clinics, vol. 7 no. 4 (October, 2011), pp. 529-37, ISSN 1551-7136 [doi]  [abs]
  5. SD Reed, CD Scales Jr, SB Stewart, J Sun, JW Moul, KA Schulman, J Xu, Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer., The Journal of urology, vol. 185 no. 3 (March, 2011), pp. 841-7, ISSN 1527-3792 [doi]  [abs]
  6. M Barbieri, M Drummond, F Rutten, J Cook, HA Glick, J Lis, SD Reed, M Sculpher, JL Severens, ISPOR Good Research Practices Economic Data Transferability Task Force, What do international pharmacoeconomic guidelines say about economic data transferability?, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 13 no. 8 (December, 2010), pp. 1028-37, ISSN 1524-4733 [doi]  [abs]
  7. CH Chou, SD Reed, JS Allsbrook, JL Steele, KA Schulman, MJ Alexander, Costs of vasospasm in patients with aneurysmal subarachnoid hemorrhage., Neurosurgery, vol. 67 no. 2 (August, 2010), pp. 345-51; discussion 351-2, ISSN 1524-4040 [doi]  [abs]
  8. SD Reed, DJ Whellan, Y Li, JY Friedman, SJ Ellis, IL Piña, SJ Settles, L Davidson-Ray, JL Johnson, LS Cooper, CM O'Connor, KA Schulman, HF-ACTION Investigators, Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure., Circulation. Cardiovascular quality and outcomes, vol. 3 no. 4 (July, 2010), pp. 374-81, ISSN 1941-7705 [doi]  [abs]
  9. C Moran, CA Grussemeyer, JR Spalding, DK Benjamin Jr, SD Reed, Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections., American journal of infection control, vol. 38 no. 1 (February, 2010), pp. 78-80, ISSN 1527-3296 [doi]  [abs]
  10. SD Reed, Y Li, EZ Oddone, AM Neary, MM Orr, JM Grubber, FL Graham, MK Olsen, LP Svetkey, RJ Dolor, BJ Powers, MB Adams, HB Bosworth, Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension., American journal of hypertension, vol. 23 no. 2 (February, 2010), pp. 142-8, ISSN 1941-7225 [doi]  [abs]
  11. S Kamble, MJ Telen, MA Dinan, CA Grussemeyer, SD Reed, Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement., American journal of hematology, vol. 85 no. 1 (January, 2010), pp. 79-81, ISSN 1096-8652 [doi]
  12. ME Patterson, WC Grant, SW Glickman, BM Massie, SE Ammon, PW Armstrong, JG Cleland, JF Collins, KK Teo, KA Schulman, SD Reed, Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation., Journal of cardiac failure, vol. 15 no. 10 (December, 2009), pp. 819-27, ISSN 1532-8414 [doi]  [abs]
  13. MA Dinan, CH Chou, BG Hammill, FL Graham, KA Schulman, MJ Telen, SD Reed, Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures., American journal of hematology, vol. 84 no. 11 (November, 2009), pp. 703-9, ISSN 1096-8652 [doi]  [abs]
  14. EM DeWitt, L Lin, HA Glick, KJ Anstrom, KA Schulman, SD Reed, Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank., Clinical therapeutics, vol. 31 no. 8 (August, 2009), pp. 1871-80; discussion 1858, ISSN 1879-114X [doi]  [abs]
  15. M Drummond, M Barbieri, J Cook, HA Glick, J Lis, F Malik, SD Reed, F Rutten, M Sculpher, J Severens, Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 12 no. 4 (June, 2009), pp. 409-18, ISSN 1524-4733 [doi]  [abs]
  16. C Moran, CA Grussemeyer, JR Spalding, DK Benjamin Jr, SD Reed, Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs., The Pediatric infectious disease journal, vol. 28 no. 5 (May, 2009), pp. 433-5, ISSN 0891-3668 [doi]  [abs]
  17. SD Reed, Y Li, KJ Anstrom, KA Schulman, Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 27 no. 13 (May, 2009), pp. 2185-91, ISSN 1527-7755 [doi]  [abs]
  18. SD Reed, KA Schulman, Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 12 no. 5 (May, 2009), pp. 637-40, ISSN 1524-4733 [doi]
  19. Y Li, JY Friedman, BF O'Neal, MJ Hohenboken, RI Griffiths, ME Stryjewski, JP Middleton, KA Schulman, JK Inrig, VG Fowler Jr, SD Reed, Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients., Clinical journal of the American Society of Nephrology : CJASN, vol. 4 no. 2 (February, 2009), pp. 428-34, ISSN 1555-905X [doi]  [abs]
  20. SD Reed, KJ Anstrom, DM Seils, RM Califf, KA Schulman, Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs., Health affairs (Project Hope), vol. 27 no. 5 (August, 2008), pp. w360-70, ISSN 1544-5208 [doi]  [abs]
  21. SD Reed, AM Shea, KA Schulman, Economic implications of potential changes to regulatory and reimbursement policies for medical devices., Journal of general internal medicine, vol. 23 Suppl 1 (January, 2008), pp. 50-6, ISSN 1525-1497 [doi]  [abs]
  22. SD Reed, KJ Anstrom, Y Li, KA Schulman, Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia., PharmacoEconomics, vol. 26 no. 5 (2008), pp. 435-46, ISSN 1170-7690  [abs]
  23. SD Reed, RM Califf, KA Schulman, How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation., Health affairs (Project Hope), vol. 25 no. 5 (March, 2007), pp. 1309-17, ISSN 1544-5208 [doi]  [abs]
  24. Reed SD, Califf RM, Schulman KA. Is there a price to pay for short-term savings in the clinical development of new pharmaceutical products? Drug Inf J. 2007;41:491-499.
  25. FM Torti Jr, SD Reed, KA Schulman, Analytic considerations in economic evaluations of multinational cardiovascular clinical trials., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 9 no. 5 (October, 2006), pp. 281-91, ISSN 1098-3015 [doi]  [abs]
  26. SD Reed, JJ McMurray, EJ Velazquez, KA Schulman, RM Califf, L Kober, AP Maggioni, F Van de Werf, HD White, R Diaz, V Mareev, J Murin, VALIANT Committees and Investigators, Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial., American heart journal, vol. 152 no. 3 (September, 2006), pp. 500-8, ISSN 1097-6744 [doi]  [abs]
  27. SD Reed, JI Radeva, DB Daniel, SH Mody, JB Forlenza, RS McKenzie, KA Schulman, Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial., PharmacoEconomics, vol. 24 no. 5 (2006), pp. 479-94, ISSN 1170-7690  [abs]
  28. SD Reed, JI Radeva, DB Daniel, JM Fastenau, D Williams, KA Schulman, Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia., Current medical research and opinion, vol. 21 no. 10 (October, 2005), pp. 1527-33, ISSN 0300-7995 [doi]  [abs]
  29. SD Reed, JI Radeva, KP Weinfurt, JJ McMurray, MA Pfeffer, EJ Velazquez, JS Allsbrook, LE Masselink, MA Sellers, RM Califf, KA Schulman, VALIANT Investigators, Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)., American heart journal, vol. 150 no. 2 (August, 2005), pp. 323-9, ISSN 1097-6744 [doi]  [abs]
  30. SD Reed, KJ Anstrom, A Bakhai, AH Briggs, RM Califf, DJ Cohen, MF Drummond, HA Glick, A Gnanasakthy, MA Hlatky, BJ O'Brien, FM Torti Jr, AA Tsiatis, AR Willan, DB Mark, KA Schulman, Conducting economic evaluations alongside multinational clinical trials: toward a research consensus., American heart journal, vol. 149 no. 3 (March, 2005), pp. 434-43, ISSN 1097-6744 [doi]  [abs]
  31. SD Reed, JY Friedman, JJ Engemann, RI Griffiths, KJ Anstrom, KS Kaye, ME Stryjewski, LA Szczech, LB Reller, GR Corey, KA Schulman, VG Fowler Jr, Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia., Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America, vol. 26 no. 2 (February, 2005), pp. 175-83, ISSN 0899-823X [doi]  [abs]
  32. SD Reed, KJ Anstrom, JA Ludmer, GA Glendenning, KA Schulman, Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia., Cancer, vol. 101 no. 11 (December, 2004), pp. 2574-83, ISSN 0008-543X [doi]  [abs]
  33. KJ Anstrom, SD Reed, AS Allen, GA Glendenning, KA Schulman, Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia., Cancer, vol. 101 no. 11 (December, 2004), pp. 2584-92, ISSN 0008-543X [doi]  [abs]
  34. SD Reed, PW Dillingham, AH Briggs, DL Veenstra, SD Sullivan, A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results., Medical decision making : an international journal of the Society for Medical Decision Making, vol. 23 no. 3 (September, 2003), pp. 252-64, ISSN 0272-989X  [abs]
  35. SD Reed, JY Friedman, A Gnanasakthy, KA Schulman, Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial., International journal of technology assessment in health care, vol. 19 no. 2 (2003), pp. 396-406, ISSN 0266-4623  [abs]
  36. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient Costs, Length of Stay and Mortality for Cerebrovascular Events in Community Hospitals, Neurology 2001; 57: 305-314.
  37. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with Tissue Plasminogen Activator and Inpatient Mortality in Ischemic Stroke Patients Treated in Community Hospitals, Stroke 2001; 32: 1832-40.
  38. Reed SO, Mullins CD, Magder LS. Cost-effectiveness of abciximab during routine medical practice, Pharmacoeconomics 2000; 18: 265-74.